Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	23.50B
Revenue (ttm)	4.32B
Net Income (ttm)	1.15B
Shares Out	571.42M
EPS (ttm)	2.00
PE Ratio	20.56
Forward PE	19.02
Dividend	1.26 (3.06%)
Ex-Dividend Date	May 26, 2025

Volume	3,126,919
Average Volume	3,813,668
Open	41.73
Previous Close	41.72
Day's Range	41.02 - 41.89
52-Week Range	36.49 - 52.98
Beta	-0.12
RSI	50.18
Earnings Date	Aug 22, 2025

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,773
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2024, Autobio Diagnostics's revenue was 4.47 billion, an increase of 0.62% compared to the previous year's 4.44 billion. Earnings were 1.19 billion, a decrease of -1.89%.